INTRODUCTION
The incidence of invasive fungal disease (IFD) in recipients of allogeneic hematopoietic stem-cell transplantation (alloHSCT) is reported to be 5.4% to 16 .0%. 1, 2 Prolonged neutropenia and immunosuppression contribute to the increasing risk of IFD in these patients. Although patients' outcome would be improved with the use of new antifungal agents such as broad-spectrum triazoles and echinocandins, the mortality caused by IFD is unacceptably high. 1, [3] [4] [5] [6] Shortening the period of neutropenia after conditioning and immune modulation using colony-stimulating factor (CSF) is another strategy to reduce the incidence of fungal infections.
Granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colonystimulating factor (GM-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy.
G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage. It enhances phagocytosis, superoxide generation, and fungicidal activity of neutrophils against fungi in vitro and in vivo. [7] [8] [9] [10] [11] In experimental models of hematogenous aspergillosis, there was a 36% improved survival rate in cyclophosphamide-treated animals given G-CSF and amphotericin B compared with those treated with antifungal therapy alone. 12 However, the activity of GM-CSF in stimulating production and activation is not restricted to neutrophils because it also affects monocytes and eosinophils. 8 Several studies demonstrated that GM-CSF and phagocytes play a central role in the antifungal host response.
10,11,13-15 Chen et al 16 reported that long-term pulmonary fungistasis was lost in GM-CSF knockout (GM-/GM-) mice, resulting in reduced eosinophil recruitment, delayed mononuclear cell influx into the airspace, and increased fungal pulmonary burden. Quezada et al 11 showed that intranasal GM-CSF given to immunosuppressed mice infected with pulmonary aspergillosis resulted in a six-fold reduction in the lung fungal burden compared with the control. On the basis of these results, a level B III recommendation was proposed in the 2008 practice guidelines of the Infectious Diseases Society of America for the treatment of invasive aspergillosis; the recommendation is that G-CSF or GM-CSF may be used to treat neutropenic patients with invasive pulmonary aspergillosis in addition to antifungal agents. 9 Despite the fact that G-CSF and GM-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi. However, to date, no randomized study has compared the prophylaxis antifungal effect of GM-CSF and G-CSF, especially in recipients of alloHSCT. We conducted a prospective, multicenter, open-label randomized trial to compare GM-CSF, G-CSF, and a combination of GM-CSF and G-CSF as prophylaxis against IFD in patients undergoing alloHSCT. We hypothesized that patients receiving GM-CSF will have a greater reduction in IFD than those who receive only G-CSF for infection prophylaxis.
PATIENTS AND METHODS

Patients and Treatment Protocol
From September 2009 to December 2012, we recruited consecutive patients with hematologic diseases undergoing alloHSCT at five institutions in China. Recipients between the ages of 14 and 60 years old were eligible. Exclusion criteria were evidence of proven, probable, or possible fungal infection at the time of enrollment according to the criteria of the European Organization for Research and Treatment of Cancer's Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases' Mycoses Study Group 17 ; cardiac ejection factor less than normal lower limit; AST and/or ALT Ն 2ϫ upper limit of normal; total bilirubin Ն 2.5ϫ upper limit of normal; creatinine Ն upper limit of normal; and a history of hypersensitivity to G-CSF or GM-CSF. Eligible patients were randomly assigned to receive once-daily subcutaneous GM-CSF 5 to 7 g/kg per day (molgramostim, Topleucon; Xiamen Amoytop Biotech, Xiamen, China), G-CSF 5 to 7 g/kg per day, or a combination of G-CSF 2 to 3 g/kg per day and GM-CSF 2 to 3 g/kg per day. Administration of CSFs was started on day 5 after transplantation and continued until recovery from neutropenia (absolute neutrophil count [ANC] Ͼ 1.5 ϫ 10 9 /L for 2 consecutive days). If ANC decreased to less than 1.5 ϫ 10 9 /L within 5 days after withdrawal of CSFs, the same CSF would be resumed until the ANC reached 1.5 ϫ 10 9 /L again. All patients received antimicrobial prophylaxis with oral levofloxacin 500 mg daily and antifungal prophylaxis with oral fluconazole 200 mg daily.
All patients underwent chest computed tomography scan at baseline and 2 weeks, 1 month, 2 months, and 100 days after transplantation and at the onset of fever. If the patients had pneumonia, the chest computed tomography scan would be done at 1-to 2-week intervals. Bronchoscopies and fungal cultures of blood, sputum, urine, stool, or oropharynx were performed as clinically indicated by the physician. The galactomannan antigen test (Platelia Aspergillus Ag kit; Bio-Rad Laboratories, Hercules, CA) and 1,3-␤-D-glucan test (Zhanjiang A & C Biologic, Zhanjiang. China; China Food and Drug Administration-approved diagnostic kit) were routinely performed before enrollment onto the trial and then once a week for the galactomannan test and twice a week for the 1,3-␤-D-glucan test after the onset of fever. A galactomannan index Ն 1.0 once or Ն 0.8 twice was defined as positive. 18 The cutoff value of 1,3-␤-D-glucan was 100 pg/mL according to the operation manual of the test manufacturer. All centers followed the protocol and did the same tests at their discretion. The diagnostic work-up was successfully performed for all patients.
Before enrollment, written informed consent was obtained from each patient or the patient's legal guardian. This trial is registered at ClinicalTials.gov (identifier: NCT01232504). The study was approved by the ethics committee of each participating center.
Random Assignment and Blinding
We randomly assigned eligible patients in a ratio of 1:1:1 to receive GM-CSF, G-CSFϩGM-CSF, or G-CSF by block randomization using randomization codes generated by SAS version 9.1 software (SAS Institute, Cary, NC). Patients, clinicians, and data analysts were not blinded to treatment allocation.
Outcomes
The primary outcomes of this trial were 100-day incidence of IFD after transplantation and patient response to antifungal treatment. IFD was diagnosed and assigned to one of three categories-proven, probable, or possible IFD-according to the revised criteria of the European Organization for Research and Treatment of Cancer's Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases' Mycoses Study Group. 17 Invasive aspergillosis was diagnosed according to the Infectious Diseases Society of America guideline for aspergillosis in 2008. 9 Patients' responses were defined as complete response, partial response, and failure according to the general criteria for global responses to antifungal therapy.
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The secondary outcomes included the recovery of ANC and platelet count, 100-day cumulative mortality, 100-day transplantation-related mortality, incidence and severity of acute graft-versus-host disease (GVHD), 1-year overall survival (OS) and disease-free survival (DFS), IFD-related mortality, infection-related mortality, relapse-related mortality, acute GVHD-related mortality, and hemorrhage-related mortality at the end of the follow-up. Death was attributed to IFD when patients died within 12 weeks from the onset of an active proven or probable IFD and if other potential causes of death could be excluded by the responsible physician. 20 Acute GVHD was defined as GVHD that occurred within 100 days after transplantation. 21 The severity of acute GVHD in the three main target organs (skin, liver, and GI tract) was assigned grade 1 to 4 based on accepted criteria.
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Safety
Incidence of adverse events, vital signs, and laboratory parameters (hematology, clinical chemistry, and urinalyses) were recorded.
Statistical Analysis
On the basis of previous reports, we expected that 20% of patients would have IFD within 100 days after transplantation. Therefore, at the start of the trial, the planned sample size for the random assignment was 198 (allowance for 10% dropout), which would give 70% power to detect a difference in IFD incidence of 5%.
We compared continuous variables among the three groups using the nonparametric Kruskal-Wallis test. Differences in categorical data were analyzed using the Mantel-Haenszel Pearson 2 test or Fisher's exact test. Sensitivity analysis and Pearson 2 tests were used to compare 100-day incidence of proven and probable IFD. The 1-year OS and DFS were estimated using the Kaplan-Meier method. The 95% CIs for 1-year OS and DFS were estimated using the Greenwood method based on variance formula. 23 Cumulative mortality and OS were compared using the logrank test. We used a multivariable Cox proportional hazards regression model to assess the relationship between prognostic factors and survival time. We used the binomial distribution exact method to construct binomial proportion CIs and the normal approximation method to construct CIs of cumulative mortality. All statistical tests were performed using SPSS 16.0 (SPSS, Chicago, IL). All analyses were by intention to treat; a twosided P Ͻ .05 was considered significant.
RESULTS
Patients
We randomly assigned 206 patients. Twelve patients were subsequently considered to be ineligible, and seven patients did not receive therapy according to their allocation (Fig 1) . Baseline characteristics among the three groups were well balanced, except the GM-CSF group, which had more male patients than the G-CSFϩGM-CSF group (75.0% [51 of 68 patients] v 53.6% [37 of 69 patients], respectively; P ϭ .012). There were no significant differences among the three groups in age, diagnosis, disease status, donor types, source of stem cells, the total number of CD34 ϩ cells and mononuclear cells, intensity of conditioning regimen, history of fungal infection, implantation of deep vein catheter, episodes of neutropenia of more than 10 days in duration in last 2 months, or long-term or repeated use of glucocorticoid. Patient characteristics are listed in Table 1 . Patients were observed up for a median of 600 days (range, 3 to 1,106 days) after transplantation. Treatment outcomes are listed in Table 2 .
IFDs
Within 100 days after transplantation, five patients were diagnosed as having proven IFD, 26 patients as probable IFD, and 24 patients as possible IFD. The 100-day incidences of proven and probable IFD were 11.76% (eight of 68 patients) for GM-CSF prophylaxis, 10.14% (seven of 69 patients) for G-CSFϩGM-CSF prophylaxis, and 23.19% (16 of 69 patients) for G-CSF prophylaxis, which were significant different by sensitivity analysis (Appendix Table A1 , online only) but similar using Pearson 2 tests (P ϭ .068). IFD was usually identified after 21 days of transplantation, most patients were given echinocandins (micafungin or caspofungin) and/or triazoles (itraconazole or voriconazole), and only two patients were treated with amphotericin B. There were no significant differences in the antifungal treatment among the three groups (P ϭ .084). Although the antifungal treatment responses were similar among the three groups 100 days after transplantation (P ϭ .053), responses were better in GM-CSFcontaining groups than in the G-CSF group from day 22 to day 100 (P ϭ .009).
In 31 patients with proven and probable IFD, mycologic tests showed that 14 patients had mold infections and 17 patients had yeast infections. The incidence of mold infection was similar among the three groups. However, the GM-CSF-containing groups had a significantly lower incidence of yeast infection (P ϭ .0173). Most of the yeast infections were caused by Candida species (Table 2) .
Hematologic Engraftment
The median time to neutrophil recovery to 0.5 ϫ 10 9 /L was slightly prolonged in the GM-CSF group (13 days) compared with the G-CSF (11 days) and G-CSFϩGM-CSF groups (11 days; P ϭ .012). The GM-CSF and G-CSFϩGM-CSF groups had shorter times to platelet recovery to 50 ϫ 10 9 /L than the G-CSF group (18, 19 , and 25 days, respectively; P Ͻ .001).
From the third to the fifth weeks after transplantation, the eosinophil count in the GM-CSF group was significantly higher than that in G-CSF group (0.043 Ϯ 0.093 v 0.027 Ϯ 0.021 = 10 9 /L, respectively; P ϭ .003). The monocyte count in the GM-CSF group was higher than that in G-CSF group in the third week after transplantation (1.14 Ϯ 0.317 v 0.637 Ϯ 0.580 = 10 9 /L, respectively; P ϭ .033). There were no differences in lymphocyte counts among the three groups. (P ϭ .644). 
Acute GVHD
In the first 100 days after transplantation, a total of 53 patients had grade Ն 2 acute GVHD. The incidence of grades 2 to 4 acute GVHD was 30.9% (21 of 68 patients; 95% CI, 20.2% to 43.3%), 24.6% (17 of 69 patients; 95% CI, 15.1% to 36.5%), and 21.7% (15 of 69 patients; 95% CI, 12.7% to 33.3%) in GM-CSF, G-CSFϩGM-CSF, and G-CSF groups, respectively. There were no significant differences among the three groups (P ϭ .473).
Survival
One hundred days after transplantation, 174 patients were alive, 10 of whom had experienced disease relapse. Thirty-two patients died; five of the 32 patients died of disease relapse, and 27 patients died of transplantation-related complications. The GM-CSF group had a lower 100-day cumulative mortality (seven of 68 patients; 10.3%; 95% CI, 4.2% to 20.1%) than the G-CSF group (17 of 69 patients; 24.6%; 95% CI, 15.1% to 36.5%; P ϭ .037). Furthermore, the 100-day cumulative transplantation-related mortality rate was lower in the GM-CSF group (six of 68 patients; 8.8%; 95% CI, 3.3% to 18.2%) and G-CSFϩGM-CSF group (six of 69 patients; 8.7%; 95% CI, 3.3% to 17.9%) than in the G-CSF group (15 of 69 patients; 21.7%; 95% CI, 12.7% to 33.3%; P ϭ .034; Fig 2) .
After a median follow-up of 600 days (range, 3 to 1,106 days), 76.7% of patients (158 of 206 patients) were alive, six of whom had experienced disease relapse, whereas 23.3% of patients (48 of 206 patients) had died. The 1-year OS and DFS rates were similar among the three groups. The IFD-related mortality rate was lower in the GM-CSF (1.47%; 95% CI, 0.04% to 7.92%; one of 68 patients) and Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; HD, Hodgkin lymphoma; IFD, invasive fungal disease; MDS, myelodysplastic syndrome; MMUD, mismatched unrelated donor; MNC, mononuclear cell; MRD, matched related donor; MUD, matched unrelated donor; NHL, non-Hodgkin lymphoma; SAA, severe aplastic anemia.
G-CSFϩGM-CSF groups (1.45%; 95% CI, 0.04% to 7.8%; one of 69 patients) than in the G-CSF group (11.59%; 95% CI, 5.14% to 21.57%; eight of 69 patients; P ϭ .016). Furthermore, the infectionrelated mortality rate was lower in the GM-CSF group (1.47%; 95% CI, 0.04% to 7.92%; one of 68 patients) than in the G-CSF group (14.49%; 95% CI, 6.42% to 22.05%; 10 of 69 patients; P ϭ .011). There were no significant differences in relapse-related, acute GVHDrelated, or hemorrhage-related mortality among the three groups (Table 3) . We compared the overall mortality using different covariates, such as group, age, sex, stem-cell numbers, disease status, proven and probable IFD, acute GVHD, and so on; only proven and probable IFD, relapse, acute GVHD, and age were independent predictive factors for OS (Table 4) . After adjustment for potential confounders, the risk of death was 4.496 times (95% CI, 2.510 to 8.050 times) higher in patients with proven and probable IFD versus patients without IFD.
DISCUSSION
In this randomized trial of recipients of alloHSCT, we showed that 100-day cumulative mortality and 100-day transplantation-related Abbreviations: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor; IFD, invasive fungal disease. Cumulative mortality 100 days after transplantation. The granulocyte-macrophage colony-stimulating factor (GM-CSF) group had significantly lower cumulative mortality than the granulocyte colony-stimulating factor (G-CSF) group (P ϭ .037). (B) Cumulative transplantation-related mortality 100 days after transplantation. The GM-CSF and G-CSFϩGM-CSF groups had significantly lower cumulative transplantation-related mortality than the G-CSF group (P ϭ .034). Plus signs indicate (A) patients lost to follow-up or (B) patients lost to follow-up or who died as a result of disease progression or relapse. Number of patients at risk is shown for each group at each time point below the figures.
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www.jco.org mortality were lower in the GM-CSF group than in the G-CSF group. After a median of 600 days of follow-up, infection-related mortality was significantly lower in the GM-CSF group than in the G-CSF group, and IFD-related mortality was significantly lower in the GM-CSF-containing groups than in the G-CSF group. There were no significant differences in relapse, GVHD, or hemorrhage-related mortality among the three groups.
This clinical trial included many high-risk patients with refractory or relapsed disease, and more than 20% of patients received grafts from haploidentical matched related donors or mismatched unrelated donors, which might account for the high 100-day mortality. However, these high-risk patients were assigned evenly to the three groups, which would not affect the comparative analysis of different groups.
The concept of cytokine-based immunotherapy for the prevention and treatment of IFD in transplantation recipients was based on the results of in vitro and in vivo studies. Neutrophils and monocytes are the most important immune cells against fungal infection. For patients receiving HSCT, conditioning regimens inevitably cause the reduction of granulocytes and monocytes and thus increase the risk of subsequent infection. CSFs can accelerate the blood cell recovery after HSCT. Our results in this study are consistent with those of Peter et al, 24 who reported that GM-CSF could reduce the incidence of systemic fungal infection and systemic fungal infection-related mortality in patients receiving high-dose chemotherapy. Similarly, Clark et al 25 reported in a meta-analysis that the use of GM-CSF was associated with statistically significant reductions in documented infections (P Ͻ .001), whereas G-CSF did not show a significant reduction (P ϭ .2). However, the authors in that study did not further evaluate the type of infection (eg, bacterial, viral, or fungal) in patients treated with G-CSF and GM-CSF. Another meta-analysis found that prophylactic G-CSF or GM-CSF in stem-cell transplantation recipients reduced the risk of documented infection but did not decrease infection-related mortality. 26 However, our study found that prophylactic GM-CSF in alloHSCT recipients could reduce infection-related mortality and IFD-related mortality but has no effect on OS and DFS at the end of follow-up; however, GM-CSF did not increase relapse or the incidence of acute GVHD. Long-term OS and DFS rates were affected by many factors, such as disease relapse, GVHD, and infection, which might not be improved by short-term administration of CSFs. We also observed higher response rates of antifungal treatment in the GM-CSF and G-CSFϩGM-CSF groups than the G-CSF group from day 22 to day 100 after transplantation. We found significant differences in the 100-day incidence of proven and probable IFD in the sensitivity analysis when assuming that all dead patients had IFD; however, the differences disappeared in Pearson 2 analysis by calculating patients with proven and probable IFD.
Our findings could be explained by the following factors. First, GM-CSF acts to increase the number of tissue macrophages in addition to the number of circulating neutrophils, monocytes, and eosinophils. 8 Our results showed that the patients in the GM-CSF group had a higher eosinophil count than those in the G-CSF group from the third to fifth weeks after transplantation, and a higher monocyte count was observed in the two GM-CSF-containing groups in the third week after transplantation. This is significant because macrophages serve as important effector cells in immune response against fungal infections. 27-31 Second, GM-CSF increases the phagocytic activity of neutrophils and monocytes against Aspergillus fumigatus and, at the same time, prevents in vitro dexamethasone-induced suppression of monocyte activity against this pathogen.
32, 33 Finally, some studies have demonstrated that GM-CSF is superior to G-CSF in priming polymorphonuclear leukocytes/peripheral-blood mononuclear cells (PMNLs/PBMCs). Gaviria et al 34 reported that GM-CSF significantly increased PMNL/PBMC-mediated fungicidal activity against both Fusarium solani and Candida albicans, whereas G-CSF priming of PMNLs/PBMCs for antifungal activity was limited to F solani. 34 In addition, Sullivan et al 35 demonstrated that G-CSF displayed much smaller effects on superoxide release from neutrophils than those from recombinant human GM-CSF. Similar results were observed in neutrophils from patients with HIV. 36 Our results were consistent with the previous studies.
It has been estimated that 20% to 50% of all patients who receive transplantation will experience grade Ն 2 acute GVHD despite immunosuppressive prophylaxis. 37 There were no differences in the incidence of grade 2 to 4 acute GVHD among the three groups in our trial. In addition, the groups receiving GM-CSF had a significantly shorter time to platelet recovery compared with the group that received G-CSF alone, which provides an additional benefit to GM-CSF. 38 In conclusion, in this randomized trial of GM-CSF for prophylaxis of infection after allogeneic transplantation, our data show that GM-CSF was more effective than G-CSF alone in decreasing 100-day cumulative mortality, 100-day transplantation-related mortality, and 600-day IFD-and infection-related mortality. Therefore, GM-CSF may be preferred in recipients of alloHSCT during periods of neutropenia to reduce infections and infection-related mortality.
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